Full Text
PCN86 DRUG UTILIZATION AND COST CONSIDERATIONS OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

Abstract

Authors

F Laliberte RS Mckenzie P Lefebvre B Bookhart F Vekeman M Duh CT Piech

Back to Volume 11, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×